Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

RecruitingRare disease

Study on the Safety and Effects of CRD-4730 for Patients with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Verified siteInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a condition known as Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). CPVT is a rare heart rhythm disorder that can cause irregular heartbeats, especially during physical activity or stress. The study will evaluate a new treatment called CRD-4730, which is a tablet designed to help manage this condition. CRD-4730 works as a small molecule inhibitor, targeting specific proteins involved in heart rhythm regulation.

The purpose of the study is to assess the safety and tolerability of CRD-4730 in individuals with CPVT. Participants will receive either the CRD-4730 tablet or a matching placebo. The study is designed as a crossover trial, meaning participants will receive both the treatment and the placebo at different times. This approach helps researchers compare the effects of the actual medication against the placebo. The study will involve repeated doses of the medication over a period of time, allowing researchers to monitor how the body processes the drug and its impact on heart rhythm.

Throughout the study, participants will be closely monitored for any side effects or changes in their condition. The trial aims to provide valuable information on how CRD-4730 can be used to improve the management of CPVT, potentially offering a new treatment option for those affected by this challenging condition.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial visit

    Upon joining the study, you will attend an initial visit. During this visit, your general health will be assessed through medical history, laboratory tests, vital sign measurements, and a physical examination. An electrocardiogram (ECG) will also be performed to check your heart's electrical activity.

  2. Step 2

    Medication administration

    You will be given a medication called CRD-4730 or a placebo, which looks like the medication but does not contain the active ingredient. The medication is in the form of a tablet and is taken orally. The exact dosage and frequency will be provided by the study team.

  3. Step 3

    Treatment period

    During the treatment period, you will take the medication as instructed. This period involves repeated doses over a specified timeframe. The study team will monitor your health and any changes in your condition.

  4. Step 4

    Follow-up visits

    You will have follow-up visits where the study team will assess the safety and tolerability of the medication. These visits will include health assessments similar to the initial visit, such as ECGs and laboratory tests.

  5. Step 5

    End of study

    At the end of the study, a final assessment will be conducted. This will include a review of your health status and any effects of the medication. The study team will provide you with information about the next steps and any necessary follow-up care.

Who can join the trial?

16 criteria

  • The participant must be able to understand and sign a consent form, agreeing to follow the study rules.
  • The participant must be a male or female who is at least 18 years old and considered an adult by local laws.
  • The participant should be in good general health, except for their diagnosis of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). This will be checked through medical history, lab tests, heart tests, and a physical exam.
  • The participant must have a confirmed diagnosis of CPVT, based on genetic testing for a specific mutation and symptoms that match CPVT. Previous genetic test results are acceptable if confirmed by the study doctor.
  • The participant must be able to perform an exercise stress test (EST) where certain heart rhythm issues are identified by the study doctor.
  • The participant must have been on a stable dose of at least one heart rhythm medication (excluding amiodarone) for four weeks before the study, unless they couldn't tolerate such medications before.
  • Female participants must meet one of the following:
    • Be postmenopausal, meaning no menstrual periods for 12 months and a specific hormone level is met.
    • Be permanently sterile, meaning unable to have children due to surgery.
    • Agree to use one highly effective birth control method and one additional barrier method until a certain time after the last dose of the study drug.
    • Have a sterilized male partner, meaning the partner cannot father children.
    • Agree to practice true abstinence, meaning no sexual activity.
    • Male participants must meet one of the following:
      • Be sterilized, meaning unable to father children due to surgery, and agree to use a condom for a certain time after the last dose of the study drug.
      • Agree to use a condom if their partner can become pregnant, and ensure the partner uses a highly effective birth control method during this time.
      • Agree to use a condom if their partner cannot become pregnant, for a certain time after the last dose of the study drug.
      • Agree not to donate sperm from the start of the study until a certain time after the last dose of the study drug.
      • Agree to practice true abstinence, meaning no sexual activity, and not donate sperm during the study period.

Who cannot join the trial?

8 criteria

  • Participants cannot have any other serious heart conditions besides Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT).
  • Participants should not have any severe medical conditions that could interfere with the study.
  • Participants must not be taking any medications that could affect the study results.
  • Participants should not have a history of drug or alcohol abuse.
  • Participants must not be pregnant or breastfeeding.
  • Participants should not have participated in another clinical trial recently.
  • Participants must not have any allergies to the study medication or its ingredients.
  • Participants should not have any mental health conditions that could affect their ability to participate in the study.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

CRD-4730 is a medication being studied for its potential to help people with a heart condition called catecholaminergic polymorphic ventricular tachycardia (CPVT). This condition can cause irregular heartbeats, especially during physical activity or stress. The medication is being tested to see if it is safe and well-tolerated when taken multiple times. Researchers are also looking at how the body processes the medication and how it affects the heart. The goal is to find out if CRD-4730 can help manage the symptoms of CPVT and improve the quality of life for those affected by this condition.

What is already known about the treatment

CRD-4730 – CRD-4730 is a medication currently being studied in a clinical trial for its potential use in treating catecholaminergic polymorphic ventricular tachycardia (CPVT), a condition that affects the heart's rhythm. It is administered in a form that allows for repeated doses, although the specific method of application is not detailed. The trial aims to evaluate the safety and tolerability of CRD-4730, meaning researchers are looking to see if it is safe for people to use and how well people can handle taking it. The medication works at the molecular level by influencing certain pathways in the body that are involved in heart rhythm regulation, although the exact mechanism is not specified. It falls under the pharmacological classification of drugs that target heart rhythm disorders.

Investigated diseases

Catecholaminergic Polymorphic Ventricular Tachycardia – This is a genetic heart condition characterized by an abnormal heart rhythm, known as ventricular tachycardia, which is triggered by physical activity or stress. The condition is caused by mutations in genes that affect calcium regulation in heart cells. During episodes, the heart beats rapidly and irregularly, which can lead to dizziness or fainting. The arrhythmias typically occur in the absence of structural heart disease and are not present at rest. Over time, repeated episodes can lead to more frequent symptoms. The condition is often diagnosed in childhood or adolescence.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-515564-32-00Protocol codeCRD-4730-202Estimated enrolment12 patientsSponsorCardurion Pharmaceuticals Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).